Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 56
Filter
2.
Sci Rep ; 6: 33118, 2016 09 09.
Article in English | MEDLINE | ID: mdl-27609184

ABSTRACT

We have fabricated a high mobility device, composed of a monolayer graphene flake sandwiched between two sheets of hexagonal boron nitride. Conductance fluctuations as functions of a back gate voltage and magnetic field were obtained to check for ergodicity. Non-linear dynamics concepts were used to study the nature of these fluctuations. The distribution of eigenvalues was estimated from the conductance fluctuations with Gaussian kernels and it indicates that the carrier motion is chaotic at low temperatures. We argue that a two-phase dynamical fluid model best describes the transport in this system and can be used to explain the violation of the so-called ergodic hypothesis found in graphene.

3.
Neuroscience ; 300: 246-53, 2015 Aug 06.
Article in English | MEDLINE | ID: mdl-25999296

ABSTRACT

Depression is one of the most common psychiatric symptoms in patients with Parkinson's disease (PD). Some authors have reported that depression is characterized by activation of the inflammatory response. Animal models of PD also present with depressive-like behavior, such as increased immobility time in the modified forced swim test and anhedonia-like behavior in the sucrose preference test. Considering the potential neuroprotective effect of nonsteroidal antiinflammatory drugs in neurodegenerative diseases, the objective of the present study was to investigate the effects of piroxicam on depressive-like behavior in male Wistar rats lesioned with 6-hydroxydopamine (6-OHDA) in the substantia nigra (SN). Antidepressant-like effects were observed after prolonged administration of piroxicam for 21days. In the forced swim test, the 6-OHDA+saline group exhibited significant reductions in swimming time and increased immobility time compared with the sham+saline. In the sucrose preference test, the 6-OHDA+piroxicam group exhibited no reduction of sucrose preference compared with the sham+saline, with significant effects of treatment and time and a significant treatment×time interaction. 5-Hydroxytryptamine (5-HT) levels significantly decreased in the hippocampus in the 6-OHDA+saline group and not changed in the 6-OHDA+piroxicam group when compared with the sham+saline on day 21. In conclusion, 21-day treatment with piroxicam reversed the onset of depressive-like behavior and prevented the reduction of hippocampal 5-HT levels.


Subject(s)
Antidepressive Agents/pharmacology , Depressive Disorder/drug therapy , Depressive Disorder/physiopathology , Parkinsonian Disorders/physiopathology , Piroxicam/pharmacology , Anhedonia/drug effects , Anhedonia/physiology , Animals , Anti-Inflammatory Agents, Non-Steroidal/pharmacology , Depressive Disorder/pathology , Dietary Sucrose , Hippocampus/drug effects , Hippocampus/metabolism , Hydroxyindoleacetic Acid/metabolism , Male , Neurons/drug effects , Neurons/pathology , Oxidopamine , Parkinsonian Disorders/pathology , Parkinsonian Disorders/psychology , Random Allocation , Rats, Wistar , Serotonin/metabolism , Substantia Nigra/drug effects , Substantia Nigra/pathology , Swimming/psychology
4.
J Phys Condens Matter ; 26(19): 193202, 2014 May 14.
Article in English | MEDLINE | ID: mdl-24763258

ABSTRACT

Scanning gate microscopy (SGM) is a novel technique that has been used to image characteristic features related to the coherent electron flow in mesoscopic structures. For instance, SGM has successfully been applied to study peculiar electron transport properties that arise due to small levels of disorder in a system. The particular case of an InGaAs quantum well layer in a heterostructure, which is dominated by a quasi-ballistic regime, was analyzed. A quantum point contact fabricated onto this material exhibits conduction fluctuations that are not expected in typical high-mobility heterostructures such as AlGaAs/GaAs. SGM revealed not only interference patterns corresponding to specific conductance fluctuations but also mode-dependent resistance peaks corresponding to the first and second quantum levels of conductance (2e(2)/h) at zero magnetic field. On the other hand, clear conductance plateaus originating from the integer quantum Hall effect were observed at high magnetic fields. The physical size of incompressible edge channels was estimated from cross-sectional analysis of these images.


Subject(s)
Microscopy/methods , Quantum Theory , Alloys/chemistry , Magnetic Fields
5.
Parkinsons Dis ; 2010: 238491, 2010 Sep 26.
Article in English | MEDLINE | ID: mdl-20976080

ABSTRACT

A previous study from our laboratory revealed that moderate nigral dopaminergic degeneration caused emotional and cognitive deficits in rats, paralleling early signs of Parkinson's disease. Recent evidence suggests that the blockade of cannabinoid CB(1) receptors might be beneficial to alleviate motor inhibition typical of Parkinson's disease. Here, we investigated whether antagonism of CB(1) receptors would improve emotional and cognitive deficits in a rat model of premotor Parkinson's disease. Depression-like behavior and cognition were assessed with the forced swim test and the social recognition test, respectively. Confirming our previous study, rats injected with 6-hydroxydopamine in striatum presented emotional and cognitive alterations which were improved by acute injection of SR141716A. HPLC analysis of monoamine levels demonstrated alterations in the striatum and prefrontal cortex after SR141716A injection. These findings suggest a role for CB(1) receptors in the early symptoms caused by degeneration of dopaminergic neurons in the striatum, as observed in Parkinson's disease.

7.
Neurotox Res ; 15(4): 359-66, 2009 May.
Article in English | MEDLINE | ID: mdl-19384569

ABSTRACT

Nicotinic drugs have been proposed as putative drugs to treat Parkinson's disease (PD). In this study, we investigated whether nicotine can sensitize parkinsonian animals to the effect of dopaminergic drugs. Testing this hypothesis is important because nicotine has been shown to present neuroprotective and acute symptomatic effects on PD, but few studies have addressed the question of whether it may induce long-lasting effects on dopamine neurotransmission. We tested this hypothesis in the 6-hydroxydopamine (6-OHDA) rat model of PD. A pretreatment of these rats with 0.1-1.0 mg/kg nicotine induced a dose-dependent sensitization of the turning behavior when the animals were challenged with the dopamine receptor agonist apomorphine 24 h later. In agreement with previous studies, while apomorphine induced contraversive turns, nicotine, as well as amphetamine, induced ipsiversive turns in the 6-OHDA rats. This result suggests that, like amphetamine, nicotine induces turning behavior by promoting release of dopamine in the non-lesioned striatum of the rats. However, it is unlikely that the release of dopamine may also explain the nicotine-induced sensitization of turning behavior. First, the dopamine amount that could be released in the lesioned hemi-striatum by the nicotine pretreatment was minimum-less than 3%, as detected by HPLC-EC. Second, a pretreatment with amphetamine did not induce this behavioral sensitization. A pretreatment with apomorphine-induced sensitization, but it was minimal when compared to that induced by nicotine. Therefore, it is unlikely that the sensitization of the turning behavior induced by nicotine was consequent of the release of dopamine. However, the expression of such sensitization seems to depend on the activation of dopaminergic receptors, since it was seen when the nicotine-sensitized animals were challenged with apomorphine, but not with a second nicotine challenge. These findings are relevant for PD drug therapy since they suggest that the doses of dopaminergic drugs used to treat PD could be reduced if a nicotinic drug were co-administered.


Subject(s)
Adrenergic Agents/toxicity , Behavior, Animal/drug effects , Functional Laterality/drug effects , Ganglionic Stimulants/pharmacology , Nicotine/pharmacology , Oxidopamine/toxicity , Analysis of Variance , Animals , Apomorphine , Chromatography, High Pressure Liquid/methods , Corpus Striatum/drug effects , Disease Models, Animal , Dopamine/metabolism , Dose-Response Relationship, Drug , Electrochemistry/methods , Male , Parkinson Disease/etiology , Parkinson Disease/physiopathology , Rats , Rats, Wistar , Time Factors
8.
Neuroscience ; 156(4): 830-40, 2008 Oct 28.
Article in English | MEDLINE | ID: mdl-18817851

ABSTRACT

In addition to classic motor symptoms, Parkinson's disease (PD) is characterized by cognitive and emotional deficits, which have been demonstrated to precede motor impairments. The present study addresses the question of whether a partial degeneration of dopaminergic neurons using 6-hydroxydopamine (6-OHDA) in rats is able to induce premotor behavioral signs. The time-course of nigrostriatal damage was evaluated by tyrosine hydroxylase immunohistochemistry and the levels of dopamine, noradrenaline, and 5-HT in various brain regions were analyzed by high performance liquid chromatography (HPLC). Behavioral tests that assessed a variety of psychological functions, including locomotor activity, emotional reactivity and depression, anxiety and memory were conducted on 6-OHDA lesioned rats. Bilateral infusion of 6-OHDA in the striatum of rats caused early (1 week) damage of dopaminergic terminals in striatum and in cell bodies in substantia nigra pars compacta. The nigrostriatal lesion was accompanied by early loss of dopamine in the striatum, which remained stable through a 3-week period of observation. In addition, a late (3 weeks) loss of dopamine in the prefrontal cortex, but not in the hippocampus, was seen. Additional noradrenergic and serotonergic alterations were observed after 6-OHDA administration. The results indicated that 6-OHDA lesioned rats show decreased sucrose consumption and an increased immobility time in the forced swimming test, an anhedonic-depressive-like effect. In addition, an anxiogenic-like activity in the elevated plus maze test and cognitive impairments were observed on the cued version of the Morris water maze and social recognition tests. These findings suggest that partial striatal dopaminergic degeneration and parallel dopaminergic, noradrenergic and serotonergic alterations in striatum and prefrontal cortex may have caused the emotional and cognitive deficits observed in this rat model of early phase PD.


Subject(s)
Affective Symptoms/etiology , Brain Chemistry/physiology , Cognition Disorders/etiology , Parkinson Disease/complications , Parkinson Disease/metabolism , Adrenergic Agents/toxicity , Analysis of Variance , Animals , Behavior, Animal , Brain/metabolism , Brain/pathology , Brain Chemistry/drug effects , Disease Models, Animal , Food Preferences/drug effects , Male , Maze Learning/drug effects , Maze Learning/physiology , Motor Activity/drug effects , Motor Activity/physiology , Oxidopamine/toxicity , Parkinson Disease/etiology , Parkinson Disease/pathology , Rats , Rats, Wistar , Reaction Time/drug effects , Reaction Time/physiology , Recognition, Psychology/drug effects , Recognition, Psychology/physiology , Time Factors , Tyrosine 3-Monooxygenase/metabolism
9.
Braz J Med Biol Res ; 40(1): 89-96, 2007 Jan.
Article in English | MEDLINE | ID: mdl-17225001

ABSTRACT

There is a great concern in the literature for the development of neuroprotectant drugs to treat Parkinson's disease. Since anesthetic drugs have hyperpolarizing properties, they can possibly act as neuroprotectants. In the present study, we have investigated the neuroprotective effect of a mixture of ketamine (85 mg/kg) and xylazine (3 mg/kg) (K/X) on the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) or 6-hydroxydopamine (6-OHDA) rat models of Parkinson's disease. The bilateral infusion of MPTP (100 microg/side) or 6-OHDA (10 microg/side) into the substantia nigra pars compacta of adult male Wistar rats under thiopental anesthesia caused a modest (~67%) or severe (~91%) loss of tyrosine hydroxylase-immunostained cells, respectively. On the other hand, an apparent neuroprotective effect was observed when the rats were anesthetized with K/X, infused 5 min before surgery. This treatment caused loss of only 33% of the nigral tyrosine hydroxylase-immunostained cells due to the MPTP infusion and 51% due to the 6-OHDA infusion. This neuroprotective effect of K/X was also suggested by a less severe reduction of striatal dopamine levels in animals treated with these neurotoxins. In the working memory version of the Morris water maze task, both MPTP- and 6-OHDA-lesioned animals spent nearly 10 s longer to find the hidden platform in the groups where the neurotoxins were infused under thiopental anesthesia, compared to control animals. This amnestic effect was not observed in rats infused with the neurotoxins under K/X anesthesia. These results suggest that drugs with a pharmacological profile similar to that of K/X may be useful to delay the progression of Parkinson's disease.


Subject(s)
Anesthetics, Combined/administration & dosage , Ketamine/administration & dosage , Neuroprotective Agents/administration & dosage , Parkinson Disease/drug therapy , Substantia Nigra/drug effects , Xylazine/administration & dosage , 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine , Anesthetics, Combined/pharmacology , Animals , Biogenic Monoamines/metabolism , Corpus Striatum/metabolism , Disease Models, Animal , Immunohistochemistry , Ketamine/pharmacology , Male , Maze Learning/drug effects , Maze Learning/physiology , Neuroprotective Agents/pharmacology , Oxidopamine , Parkinson Disease/metabolism , Parkinson Disease/pathology , Rats , Rats, Wistar , Substantia Nigra/metabolism , Substantia Nigra/pathology , Thiopental/administration & dosage , Thiopental/pharmacology , Tyrosine 3-Monooxygenase/metabolism , Xylazine/pharmacology
10.
Braz. j. med. biol. res ; 40(1): 89-96, Jan. 2007. ilus, graf
Article in English | LILACS | ID: lil-439667

ABSTRACT

There is a great concern in the literature for the development of neuroprotectant drugs to treat Parkinson's disease. Since anesthetic drugs have hyperpolarizing properties, they can possibly act as neuroprotectants. In the present study, we have investigated the neuroprotective effect of a mixture of ketamine (85 mg/kg) and xylazine (3 mg/kg) (K/X) on the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) or 6-hydroxydopamine (6-OHDA) rat models of Parkinson's disease. The bilateral infusion of MPTP (100 æg/side) or 6-OHDA (10 æg/side) into the substantia nigra pars compacta of adult male Wistar rats under thiopental anesthesia caused a modest (~67 percent) or severe (~91 percent) loss of tyrosine hydroxylase-immunostained cells, respectively. On the other hand, an apparent neuroprotective effect was observed when the rats were anesthetized with K/X, infused 5 min before surgery. This treatment caused loss of only 33 percent of the nigral tyrosine hydroxylase-immunostained cells due to the MPTP infusion and 51 percent due to the 6-OHDA infusion. This neuroprotective effect of K/X was also suggested by a less severe reduction of striatal dopamine levels in animals treated with these neurotoxins. In the working memory version of the Morris water maze task, both MPTP- and 6-OHDA-lesioned animals spent nearly 10 s longer to find the hidden platform in the groups where the neurotoxins were infused under thiopental anesthesia, compared to control animals. This amnestic effect was not observed in rats infused with the neurotoxins under K/X anesthesia. These results suggest that drugs with a pharmacological profile similar to that of K/X may be useful to delay the progression of Parkinson's disease.


Subject(s)
Animals , Male , Rats , Anesthetics, Combined/administration & dosage , Ketamine/administration & dosage , Neuroprotective Agents/administration & dosage , Parkinson Disease/drug therapy , Substantia Nigra/drug effects , Xylazine/administration & dosage , Anesthetics, Combined/pharmacology , Biogenic Monoamines/metabolism , Corpus Striatum/metabolism , Disease Models, Animal , Immunohistochemistry , Ketamine/pharmacology , Maze Learning/drug effects , Maze Learning/physiology , Neuroprotective Agents/pharmacology , Oxidopamine , Parkinson Disease/metabolism , Parkinson Disease/pathology , Rats, Wistar , Substantia Nigra/metabolism , Substantia Nigra/pathology , Thiopental/administration & dosage , Thiopental/pharmacology , /metabolism , Xylazine/pharmacology
11.
Biotechnol Lett ; 28(6): 447-53, 2006 Mar.
Article in English | MEDLINE | ID: mdl-16614912

ABSTRACT

Newly designed group-specific PCR primers for denaturing gradient gel electrophoresis (DGGE) were used to investigate foaming mycolata from a bioreactor treating an industrial saline waste-water. Genetic profiles on DGGE gels were different with NaCl at 1.65 and 8.24 g l(-1), demonstrating that mycolata community was affected by salinity. A semi-nested PCR strategy resulted in more bands in community genetic profiles than direct amplification. DNA sequencing of bands confirmed the efficacy of the novel primers with sequences recovered being most similar to foam producing mycolata. The new group-specific primers/DGGE approach is a new step toward a more complete understanding of functionally important groups of bacteria involved in biological treatment of waste-water.


Subject(s)
Actinobacteria/genetics , DNA Primers/genetics , Industrial Waste/analysis , Polymerase Chain Reaction/methods , Waste Management/methods , Actinobacteria/isolation & purification , Biodegradation, Environmental , Ecosystem , Electrophoresis, Polyacrylamide Gel , Mycolic Acids/chemistry , RNA, Ribosomal, 16S/classification , Sequence Analysis, DNA/methods , Water Purification/methods
12.
Behav Pharmacol ; 16(4): 209-18, 2005 Jul.
Article in English | MEDLINE | ID: mdl-15961960

ABSTRACT

Increasing evidence suggests that antagonistic interactions between specific subtypes of adenosine and dopamine receptors in the basal ganglia are involved in the control of motor activity. However, there are few studies investigating this interaction in other brain regions and its role in additional functions. In the present study, we evaluated whether reserpine-treated rats (1.0 mg/kg, i.p.) exhibit altered social recognition memory abilities. The effects of acute administration of the dopamine receptor agonists 7,8-dihydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3 benzazepine (SKF 38393, dopamine D(1) receptor agonist) and quinpirole (dopamine D(2) receptor agonist), together with the adenosine receptor antagonists caffeine (non-selective), 8-cyclopentyl-1,3-dipropylxanthine (DPCPX, adenosine A(1) receptor antagonist) and 4-(2-[7-amino-2-{2-furyl}{1,2,4}triazolo-{2,3-a}{1,3,5}triazin-5-yl-amino]ethyl)phenol (ZM241385, adenosine A(2A) receptor antagonist), were also investigated. Twenty-four hours after treatment, reserpine-treated rats exhibited a significant disruption in the ability to recognize a juvenile rat after a short period of time. These animals did not show any motor deficit. The social recognition disruption induced by reserpine was reversed by acute treatment with quinpirole (0.05-0.1 mg/kg, i.p.), caffeine (10.0-30.0 mg/kg, i.p.) or ZM241385 (0.5-1.0 mg/kg, i.p.), but not with SKF 38393 (0.5-3.0 mg/kg, i.p.) or DPCPX (0.5-3.0 mg/kg, i.p.). Moreover, a synergistic response was observed following the co-administration of 'non-effective' doses of ZM241385 (0.1 mg/kg, i.p.) and quinpirole (0.01 mg/kg, i.p.). These results reinforce and extend the notion of antagonistic interactions between adenosine and dopamine receptors, and demonstrate, for the first time, that the blockade of adenosine A(2A) receptors and the activation of dopamine D(2) receptors can reverse the social recognition deficits induced by reserpine in rats.


Subject(s)
Antipsychotic Agents/pharmacology , Memory/drug effects , Receptor, Adenosine A2A/drug effects , Receptors, Dopamine D2/drug effects , Recognition, Psychology/drug effects , Reserpine/pharmacology , Social Behavior , Adenosine A2 Receptor Agonists , Adenosine A2 Receptor Antagonists , Animals , Antipsychotic Agents/administration & dosage , Dopamine Agonists/pharmacology , Dopamine D2 Receptor Antagonists , Injections, Intraperitoneal , Male , Motor Activity/drug effects , Rats , Rats, Wistar , Receptors, Dopamine D2/agonists , Reserpine/administration & dosage
13.
Exp Neurol ; 192(1): 134-41, 2005 Mar.
Article in English | MEDLINE | ID: mdl-15698627

ABSTRACT

Adult male Wistar rats with bilateral substantia nigra, pars compacta (SNc) lesion induced by intranigral administration of 0.5 mumol 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) were used as a model of early phase Parkinson's disease (PD). This treatment caused loss of dopaminergic cells in the SNc and a partial depletion of striatal dopamine. Animals trained up to 80% correct choices presented significantly worse scores after SNc lesion compared to sham-operated animals and spent almost 6 days to reach this criterion again, while sham-operated animals reached this criterion within about 2 days. When naive animals had their SNc lesioned before training, they scored worse than sham-operated animals and took 18 days to reach the 80% correct choices criterion, while sham-operated controls reached this criterion after only 10 days. These results suggest that lesion of the SNc impairs working memory in rats performing this task, in agreement with the working memory impairment in PD patients reported in clinical studies.


Subject(s)
Cognition Disorders/complications , Memory Disorders/etiology , Memory, Short-Term/physiology , Parkinsonian Disorders/complications , Substantia Nigra/physiopathology , 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine , Animals , Cognition Disorders/etiology , Cognition Disorders/physiopathology , Denervation , Disease Models, Animal , Dopamine/metabolism , Male , Maze Learning/physiology , Memory Disorders/physiopathology , Memory Disorders/psychology , Models, Neurological , Neural Pathways/pathology , Neural Pathways/physiopathology , Parkinsonian Disorders/etiology , Parkinsonian Disorders/physiopathology , Rats , Rats, Wistar , Substantia Nigra/pathology
14.
Tissue Antigens ; 62(4): 308-12, 2003 Oct.
Article in English | MEDLINE | ID: mdl-12974797

ABSTRACT

The heterogeneity in the clinical expression of Chagas disease gives strong evidences for the involvement of genetic factors on its pathogenesis. Several studies have indicated different markers of genetic susceptibility to Chagas cardiomyopathy. In the present study, we present evidence of association between complement C3 and BF allotypes, and the susceptibility to Chagas disease and the development of cardiomyopathy. C3, BF, C4A, C4B and C2 polymorphism were determined in 100 seropositive Chagasic patients [cardiomyopathic (CARD), n = 57; asymptomatic indetermined (IND), n = 43] and in 100 non-related seronegative healthy controls. Patients and controls were matched according to their ethnic and geographical origin. A significantly increased frequency of C3F was observed in patients with the CARD form (8/57 14.03%), when compared with those presenting the IND form (0/43, 0%; RR 7.0) and with the healthy controls (5/100, 5%; RR 3.1). A negative association of the BF S allotype was observed in the CARD patients (19/57 33.33%) and in the Chagas total (38/100 38.0%), when compared with the controls (55/100, 55.0%; RR 0.4). All other C3, BF, C4A, C4B and C2 alleles showed no significant differences. These results suggest the allele C3F as a susceptible marker for the progression of the CARD form. On the other hand, BF S may represent a protective role against severe CARD disease. These results corroborate the importance of the alternative pathway in Trypanosoma cruzi infection and indicate possible genetic markers of Chagas cardiomyopathy.


Subject(s)
Chagas Cardiomyopathy/genetics , Complement C3/genetics , Genetic Predisposition to Disease , Adult , Aged , Blood Group Antigens/genetics , Chagas Cardiomyopathy/blood , Chagas Cardiomyopathy/immunology , Complement Activation , Complement Factor B/genetics , Female , Humans , Immunoglobulin Allotypes/genetics , Male , Middle Aged , Myocardium/pathology , Polymorphism, Genetic
15.
Braz J Med Biol Res ; 35(10): 1201-8, 2002 Oct.
Article in English | MEDLINE | ID: mdl-12424493

ABSTRACT

We studied some of the characteristics of the improving effect of the non-specific adenosine receptor antagonist, caffeine, using an animal model of learning and memory. Groups of 12 adult male Wistar rats receiving caffeine (0.3-30 mg/kg, ip, in 0.1 ml/100 g body weight) administered 30 min before training, immediately after training, or 30 min before the test session were tested in the spatial version of the Morris water maze task. Post-training administration of caffeine improved memory retention at the doses of 0.3-10 mg/kg (the rats swam up to 600 cm less to find the platform in the test session, P<=0.05) but not at the dose of 30 mg/kg. Pre-test caffeine administration also caused a small increase in memory retrieval (the escape path of the rats was up to 500 cm shorter, P<=0.05). In contrast, pre-training caffeine administration did not alter the performance of the animals either in the training or in the test session. These data provide evidence that caffeine improves memory retention but not memory acquisition, explaining some discrepancies among reports in the literature.


Subject(s)
Caffeine/pharmacology , Central Nervous System Stimulants/pharmacology , Maze Learning/drug effects , Memory/drug effects , Analysis of Variance , Animals , Caffeine/administration & dosage , Central Nervous System Stimulants/administration & dosage , Male , Rats , Rats, Wistar
16.
Behav Brain Res ; 124(1): 9-18, 2001 Sep 28.
Article in English | MEDLINE | ID: mdl-11423161

ABSTRACT

Intra-nigral administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrindine (MPTP) caused a lesion in the substantia nigra, compact part (SNc) and a specific loss of dopamine and its metabolites in the striatum of rats. The animals were then tested in the two-way active avoidance task. MPTP-treated animals presented lower learning scores in the training and test sessions, an effect that was not caused by motor impairment or by a decreased sensitivity to footshock since their reaction time to the footshock (unconditioned stimulus - UCS) was not reduced. These lower scores were also not attributable to lower acoustic sensitivity or to a slowing in the association of the sound cue (conditioned stimulus - CS) with the UCS since the reaction time to the CS in the active avoidance response did not differ between MPTP-treated and control groups. Therefore, these results are more properly attributable to an impairment of the memory acquisition and retention processes. In addition, this study is presented as a model of early Parkinson's Disease amnesia and is discussed in terms of the importance of the nigrostriatal pathway to memory acquisition and storage processes.


Subject(s)
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine , Avoidance Learning/drug effects , Mental Recall/drug effects , Parkinsonian Disorders/chemically induced , Substantia Nigra/drug effects , 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine/pharmacology , Animals , Association Learning/drug effects , Association Learning/physiology , Avoidance Learning/physiology , Conditioning, Classical/drug effects , Conditioning, Classical/physiology , Dopamine/metabolism , Male , Mental Recall/physiology , Neural Pathways/drug effects , Neural Pathways/physiopathology , Parkinsonian Disorders/physiopathology , Rats , Rats, Wistar , Retention, Psychology/drug effects , Retention, Psychology/physiology , Substantia Nigra/physiopathology
17.
Brain Res Bull ; 55(1): 101-6, 2001 May 01.
Article in English | MEDLINE | ID: mdl-11427344

ABSTRACT

The present study was carried out to test the possible effects of caffeine in improving the memory deficits observed in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrindine (MPTP)-lesioned rats, an animal model of early stage Parkinson's disease. Caffeine at the doses of 0.1-0.3 mg/kg (intraperitoneal) reversed the impairing effect of the administration of MPTP (1 micromol/side) into the substantia nigra, compact part, of rats on the avoidance scores in the training and test sessions of a two-way active avoidance task. This effect was not due to a motor or sensory alteration because the caffeine-induced learning and memory improvement was independent of the locomotor stimulant effect of the drug and there were no differences in the reaction time of the animals to a footshock (unconditioned stimulus) or a sound cue (conditioned stimulus) after caffeine treatment. These results suggest that the reported dopamine/adenosine-receptor interaction can be used to restore defective learning and memory processes in Parkinson's disease and indicate that caffeine and other adenosine receptor antagonists are drugs with the potential for treatment of the cognitive disabilities of Parkinson's disease.


Subject(s)
Caffeine/pharmacology , Central Nervous System Stimulants/pharmacology , Memory Disorders/drug therapy , Parkinsonian Disorders/complications , 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine/pharmacology , Animals , Avoidance Learning/drug effects , Avoidance Learning/physiology , Dopamine Agents/pharmacology , Dose-Response Relationship, Drug , Male , Memory Disorders/chemically induced , Memory Disorders/physiopathology , Parkinsonian Disorders/physiopathology , Rats , Rats, Wistar , Substantia Nigra/drug effects , Substantia Nigra/physiopathology
18.
Braz J Med Biol Res ; 34(3): 283-93, 2001 Mar.
Article in English | MEDLINE | ID: mdl-11262578

ABSTRACT

This article is a transcription of an electronic symposium in which active researchers were invited by the Brazilian Society of Neuroscience and Behavior (SBNeC) to discuss the advances of the last decade in the neurobiology of emotion. Four basic questions were debated: 1) What are the most critical issues/questions in the neurobiology of emotion? 2) What do we know for certain about brain processes involved in emotion and what is controversial? 3) What kinds of research are needed to resolve these controversial issues? 4) What is the relationship between learning, memory and emotion? The focus was on the existence of different neural systems for different emotions and the nature of the neural coding for the emotional states. Is emotion the result of the interaction of different brain regions such as the amygdala, the nucleus accumbens, or the periaqueductal gray matter or is it an emergent property of the whole brain neural network? The relationship between unlearned and learned emotions was also discussed. Are the circuits of the former the underpinnings of the latter? It was pointed out that much of what we know about emotions refers to aversively motivated behaviors, like fear and anxiety. Appetitive emotions should attract much interest in the future. The learning and memory relationship with emotions was also discussed in terms of conditioned and unconditioned stimuli, innate and learned fear, contextual cues inducing emotional states, implicit memory and the property of using this term for animal memories. In a general way it could be said that learning modifies the neural circuits through which emotional responses are expressed.


Subject(s)
Brain/physiology , Emotions/physiology , Learning/physiology , Neurobiology , Amygdala/physiology , Animals , Anxiety , Fear/physiology , Humans , Memory/physiology , Periaqueductal Gray/physiology
19.
Braz. j. med. biol. res ; 34(3): 283-293, Mar. 2001.
Article in English | LILACS | ID: lil-281608

ABSTRACT

This article is a transcription of an electronic symposium in which active researchers were invited by the Brazilian Society of Neuroscience and Behavior (SBNeC) to discuss the advances of the last decade in the neurobiology of emotion. Four basic questions were debated: 1) What are the most critical issues/questions in the neurobiology of emotion? 2) What do we know for certain about brain processes involved in emotion and what is controversial? 3) What kinds of research are needed to resolve these controversial issues? 4) What is the relationship between learning, memory and emotion? The focus was on the existence of different neural systems for different emotions and the nature of the neural coding for the emotional states. Is emotion the result of the interaction of different brain regions such as the amygdala, the nucleus accumbens, or the periaqueductal gray matter or is it an emergent property of the whole brain neural network? The relationship between unlearned and learned emotions was also discussed. Are the circuits of the former the underpinnings of the latter? It was pointed out that much of what we know about emotions refers to aversively motivated behaviors, like fear and anxiety. Appetitive emotions should attract much interest in the future. The learning and memory relationship with emotions was also discussed in terms of conditioned and unconditioned stimuli, innate and learned fear, contextual cues inducing emotional states, implicit memory and the property of using this term for animal memories. In a general way it could be said that learning modifies the neural circuits through which emotional responses are expressed


Subject(s)
Humans , History, 20th Century , Animals , Brain/physiology , Emotions/physiology , Learning/physiology , Neurobiology , Amygdala/physiology , Anxiety , Fear/physiology , Memory/physiology , Neurobiology/history , Periaqueductal Gray/physiology
20.
Braz J Med Biol Res ; 34(2): 145-54, 2001 Feb.
Article in English | MEDLINE | ID: mdl-11175489

ABSTRACT

This article is a transcription of an electronic symposium sponsored by the Brazilian Society of Neuroscience and Behavior (SBNeC). Invited researchers from the European Union, North America and Brazil discussed two issues on anxiety, namely whether panic is a very intense anxiety or something else, and what aspects of clinical anxiety are reproduced by animal models. Concerning the first issue, most participants agreed that generalized anxiety and panic disorder are different on the basis of clinical manifestations, drug response and animal models. Also, underlying brain structures, neurotransmitter modulation and hormonal changes seem to involve important differences. It is also common knowledge that existing animal models generate different types of fear/anxiety. A challenge for future research is to establish a good correlation between animal models and nosological classification.


Subject(s)
Anxiety , Disease Models, Animal , Panic , Anti-Anxiety Agents/pharmacology , Anxiety/drug therapy , Anxiety/physiopathology , Benzodiazepines/pharmacology , Brain/drug effects , Brain/physiopathology , Fear/drug effects , Humans , Panic/drug effects , Periaqueductal Gray/drug effects , Periaqueductal Gray/physiopathology , Serotonin/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL
...